Skip to content

Paraspinal Stimulation in Treating MPS

Paraspinal Stimulation Combined With Trigger Point Needling and Needle Rotation in Treating Myofascial Pain: Randomized Sham-controlled Clinical Trial

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01708343
Acronym
DIMMST
Enrollment
75
Registered
2012-10-16
Start date
2011-01-31
Completion date
2012-11-30
Last updated
2012-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical Study - RCT

Keywords

Myofascial Pain Syndrome,, intramuscular stimulation,, acupuncture,, sleep quality,, pain threshold.

Brief summary

To test the hypothesis that the effect of either multiple deep intramuscular stimulation therapy \[(DIMMST: trigger point deep dry needling (TrP-DDN) is combined with paraspinal deep intramuscular stimulation (PDIMS) and needle rotation (NR)\] would be more effective than a placebo-sham for the treatment of MPS and that DIMMST would be more effective than LTrP-I for improving pain relief, sleep quality, and physical and mental state of the patient.

Interventions

PROCEDUREDIMMST

Sponsors

Hospital de Clinicas de Porto Alegre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
19 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Myofascial pain syndrome (MPS) (defined as regional pain, normal neurologic examination, presence of TrPs, taut bands, tender points, and pain characterized as dull, achy, or deep were relevant to MPS diagnosis. Additionally, palpable nodules, pain that is exacerbated by stress, decreased range of motion, and ropiness in the muscle). * Disability in the last three months: (defined if they had one or more these limitation in active and routine activities by MPS : (i) interference with work, (ii) enjoyable activities, (iii) responsibilities at home, (iv) relationships, (v) personal goals, (vi) thinking clearly, and problem solving, concentrating, or remembering during the last three months). * Women * Age: 19 to 50 years

Exclusion criteria

Rheumatoid arthritis Fibromyalgia Previous surgery on the affected areas Prior experience with acupuncture Primary radiculopathy Current use of psychotropic drugs (ilicits ) Habitual use of anti-inflammatory steroids.

Design outcomes

Primary

MeasureTime frameDescription
Pain severityA cumulative mean of each week during the treatmetn period (four weeks - the pain diary begin in the first of treatment to the last session)a) The intensity of pain was measured by a 10-cm VAS \[30\]. VAS scores ranged from no pain (zero) to the worst possible pain (10 cm).
Pain thresholdA cumulative mean of each week during the treatmetn period (four weeks - the pain diary begin in the first of treatment to the last session)Pain pressure threshold (PPT)

Secondary

MeasureTime frameDescription
Sleep quality - how did you feel when you woke upA cumulative mean of each week during the treatmetn period (four weeks - the pain diary begin in the first of treatment to the last session)Sleep quality was recorded daily by the 10-cm visual analog sleep quality scale (VASQS) in the sleep diary using VASQS: In general, how did you feel when you woke up?
Sleep quality - compared to your habitual sleepA cumulative mean of each week during the treatmetn period (four weeks - the pain diary begin in the first of treatment to the last session)Sleep quality was recorded daily by the 10-cm visual analog sleep quality scale (VASQS) in the sleep diary using VASQS: Assess the sleep quality of the previous night compared to your habitual sleep?
Sleep quality -last nightA cumulative mean of each week during the treatmetn period (four weeks - the pain diary begin in the first of treatment to the last session)Sleep quality was recorded daily by the 10-cm visual analog sleep quality scale (VASQS) in the sleep diary using VASQS: How well did you sleep last night?

Other

MeasureTime frameDescription
Physical and mental HealthBefore to begin treatment and after end treatmentHealth-related quality of life, assessed at baseline and the end of treatment sessions, was measured with the SF-12 Summary Scales

Countries

Brazil

Contacts

Primary ContactWOLNEI CAUMO, MD, PhD
caumo@cpovo.net55-51-3359-8083
Backup ContactCAUMO, MD., PhD
caumo@cpovo.net55-51-3359-8083

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026